Presentation and Status in Health Basket
| Presentation | Basket | Yarpa | Pharmasoft |
|---|---|---|---|
|
Buccal Tablet 28 X 100 mcg |
|
76296 | 6551 |
|
Buccal Tablet 28 X 200 mcg |
|
76297 | 6552 |
|
Buccal Tablet 28 X 400 mcg |
|
76298 | 6553 |
|
Buccal Tablet 28 X 600 mcg |
|
76299 | 6554 |
|
Buccal Tablet 28 X 800 mcg |
|
76300 | 6555 |
Related information
Dosage
See prescribing information for full details.
Indications
Fentora is indicated for the treatment of breakthrough pain (BTP) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain.
BTP is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain.
Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.
Contra-Indications
Hypersensitivity to the active substance or to any of the excipients.
Patients without maintenance opioid therapy as there is an increased risk of respiratory depression.
Severe respiratory depression or severe obstructive lung conditions.
Treatment of acute pain other than breakthrough pain.
Special Precautions
See prescribing information for full details.
Side Effects
See prescribing information for full details.
Drug interactions
See prescribing information for full details.
Pregnancy and Lactation
See prescribing information for full details.
Overdose
See prescribing information for full details.
